Clinical Trials
24 trialsNCT05426005 2026-05-22
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Recruiting
NCT06903858 2026-05-22
PICC-3
Sun Yat-sen University
Phase 2 Recruiting
NCT03607890 2026-03-16
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT07385846 2026-02-04
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
University of Cincinnati
Phase 1 Not yet recruiting
NCT07266025 2026-01-27
CATALIS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07369986 2026-01-27
IMMUNE-SAVE
Women's Hospital School Of Medicine Zhejiang University
Phase 2 Not yet recruiting
NCT07360834 2026-01-23
PREDI-LYNCH
UNICANCER
Phase NA Not yet recruiting
NCT07259473 2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT03926338 2025-11-20
PICC
Sun Yat-sen University
Phase 2 Recruiting
NCT06215677 2025-09-05
NITDC
Peking Union Medical College Hospital
Phase NA Recruiting
NCT03935893 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
Phase 2 Recruiting
NCT05118724 2025-06-15
ANTONIO
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT06646445 2025-06-13
PREMICES
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT02983578 2025-05-06
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT05200559 2024-12-05
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
University of Pittsburgh
Phase 1/2 Recruiting
NCT06549855 2024-08-12
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Peking University People's Hospital
Phase NA Not yet recruiting
NCT04636008 2024-08-06
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
West China Hospital
Phase 1/2 Recruiting
NCT02992964 2024-04-02
Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
The Hospital for Sick Children
Phase 1/2 Terminated
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05371197 2022-05-12
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown
NCT04001101 2021-11-30
Anti-PD-1 +/- RT for MSI-H Solid Tumors
University of Colorado, Denver
Phase 2 Withdrawn
NCT03150706 2020-04-03
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Asan Medical Center
Phase 2 Unknown